Vorapaxar , a novel antiplatelet therapy , reduces thrombotic events in patients with a history of myocardial infarction ( MI ) or peripheral artery disease ( PAD ) ; however , because of an increased risk of intracranial hemorrhage , it is contraindicated in patients with a history of stroke .